Suvratoxumab (INN;[1] development code MEDI4893) is a human monoclonal antibody designed for the prevention of nosocomial pneumonia caused by Staphylococcus aureus.
This drug was developed by MedImmune[2]
Esmaspäev, märts 17, 2025
Suvratoxumab (INN;[1] development code MEDI4893) is a human monoclonal antibody designed for the prevention of nosocomial pneumonia caused by Staphylococcus aureus.
This drug was developed by MedImmune[2]
Fungal |
| ||||||||
---|---|---|---|---|---|---|---|---|---|
Viral | |||||||||
Bacterial |
| ||||||||
Toxin |
| ||||||||
|
You must be logged in to post a comment.